Before 2018 comes to a close, we wanted to say thank you to our readers from everyone here at Dermatology Times. As a thank you, we have compiled a list of the topics and issues you found most compelling throughout the year. Enjoy this slideshow - and see you in 2019!
The oral selective JAK inhibitor baricitinib may be an effective, safe option for patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 clinical trials. (©TYLim/Shutterstock)